Tags

Type your tag names separated by a space and hit enter

Tanshinone prevents cancellous bone loss induced by ovariectomy in rats.
Acta Pharmacol Sin. 2004 May; 25(5):678-84.AP

Abstract

AIM

To investigate the skeletal effects of total tanshinone in ovariectomized rats by analyzing cancellous bone histomorphometry of fourth lumbar vertebrae (LV4) and proximal tibial metaphyses (PTM).

METHODS

Four-month-old Sprague-Dawley female rats were sham-operated and treated with vehicle or ovariectomized and treated with either vehicle, total tanshinone (200 mg x kg(-1) x d(-1), equivalent to 35 microg x kg(-1) x d(-1) of tanshinone II A and 16 microg x kg(-1) x d(-1) of cryptotanshinone), or 17alpha-ethynylestradiol (30 microg x kg(-1) x d(-1) as positive treatment group) starting one day post-surgery for 10 weeks. Double in vivo fluorochrome labeling was administered to all rats. The undecalcified longitudinal LV4 and PTM sections were cut and stained with Goldner's Trichrome (4-microm thickness) or unstained (8-microm thickness) for the bone histomorphometric analysis.

RESULTS

A significant decrease in trabecular bone volume (BV/TV) and trabecular number (Tb.N) and a significant increase in osteoclast surface (OCS/BS) and mineralizing surface (MS/BS) were found in both LV and PTM of vehicle-treated OVX rats compared with sham controls. Tanshinone completely prevented the decreases in BV/TV and Tb.N and the increase in OCS/BS in the LV4, and partially prevented the decreases in BV/TV and Tb.N in the PTM of OVX rats. In addition, tanshinone increased trabecular thickness (Tb.Th) whereas it did not alter MS/BS. Moreover, tanshinone had no effect on uterine weight and body weight of OVX rats. Estrogen treatment increased BV/TV and Tb.N and decreased OCS/BS, but, also markedly decreased MS/BS and increased uterine weight in OVX rats.

CONCLUSION

The current study demonstrated that the adequate supply of tanshinone prevented OVX-induced cancellous bone loss in rats through inhibition of elevated bone resorption.

Authors+Show Affiliations

Institue of Biomedical Engineering, West China Medical Center, Sichuan University, Chengdu 610041, China. cui_liao@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15132837

Citation

Cui, Liao, et al. "Tanshinone Prevents Cancellous Bone Loss Induced By Ovariectomy in Rats." Acta Pharmacologica Sinica, vol. 25, no. 5, 2004, pp. 678-84.
Cui L, Wu T, Liu YY, et al. Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacol Sin. 2004;25(5):678-84.
Cui, L., Wu, T., Liu, Y. Y., Deng, Y. F., Ai, C. M., & Chen, H. Q. (2004). Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. Acta Pharmacologica Sinica, 25(5), 678-84.
Cui L, et al. Tanshinone Prevents Cancellous Bone Loss Induced By Ovariectomy in Rats. Acta Pharmacol Sin. 2004;25(5):678-84. PubMed PMID: 15132837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tanshinone prevents cancellous bone loss induced by ovariectomy in rats. AU - Cui,Liao, AU - Wu,Tie, AU - Liu,Yu-yu, AU - Deng,Yi-feng, AU - Ai,Chun-mei, AU - Chen,Huai-qing, PY - 2004/5/11/pubmed PY - 2004/8/11/medline PY - 2004/5/11/entrez SP - 678 EP - 84 JF - Acta pharmacologica Sinica JO - Acta Pharmacol Sin VL - 25 IS - 5 N2 - AIM: To investigate the skeletal effects of total tanshinone in ovariectomized rats by analyzing cancellous bone histomorphometry of fourth lumbar vertebrae (LV4) and proximal tibial metaphyses (PTM). METHODS: Four-month-old Sprague-Dawley female rats were sham-operated and treated with vehicle or ovariectomized and treated with either vehicle, total tanshinone (200 mg x kg(-1) x d(-1), equivalent to 35 microg x kg(-1) x d(-1) of tanshinone II A and 16 microg x kg(-1) x d(-1) of cryptotanshinone), or 17alpha-ethynylestradiol (30 microg x kg(-1) x d(-1) as positive treatment group) starting one day post-surgery for 10 weeks. Double in vivo fluorochrome labeling was administered to all rats. The undecalcified longitudinal LV4 and PTM sections were cut and stained with Goldner's Trichrome (4-microm thickness) or unstained (8-microm thickness) for the bone histomorphometric analysis. RESULTS: A significant decrease in trabecular bone volume (BV/TV) and trabecular number (Tb.N) and a significant increase in osteoclast surface (OCS/BS) and mineralizing surface (MS/BS) were found in both LV and PTM of vehicle-treated OVX rats compared with sham controls. Tanshinone completely prevented the decreases in BV/TV and Tb.N and the increase in OCS/BS in the LV4, and partially prevented the decreases in BV/TV and Tb.N in the PTM of OVX rats. In addition, tanshinone increased trabecular thickness (Tb.Th) whereas it did not alter MS/BS. Moreover, tanshinone had no effect on uterine weight and body weight of OVX rats. Estrogen treatment increased BV/TV and Tb.N and decreased OCS/BS, but, also markedly decreased MS/BS and increased uterine weight in OVX rats. CONCLUSION: The current study demonstrated that the adequate supply of tanshinone prevented OVX-induced cancellous bone loss in rats through inhibition of elevated bone resorption. SN - 1671-4083 UR - https://www.unboundmedicine.com/medline/citation/15132837/Tanshinone_prevents_cancellous_bone_loss_induced_by_ovariectomy_in_rats_ L2 - http://www.chinaphar.com/1671-4083/25/678.pdf DB - PRIME DP - Unbound Medicine ER -